Is axillary dissection needed in node-positive breast cancer?

Caprice C. Greenberg, Andrea C. Bafford, Mehra Golshan

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axillas. With the increased use of SLNB in women who present with breast carcinoma, the role of completion ALND for a positive sentinel lymph node has been challenged. We review the literature available and discuss future directions in identifying a subgroup who may avoid an ALND.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalExpert Review of Anticancer Therapy
Issue number2
StatePublished - Feb 2008
Externally publishedYes


  • Axillary node dissection
  • Breast cancer
  • Sentinel node biopsy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Is axillary dissection needed in node-positive breast cancer?'. Together they form a unique fingerprint.

Cite this